Cancer results boost Sareum

Cancer drug discovery business Sareum shot ahead after it said it had selected a "preclinical development candidate" from research into Chk1, a method of controlling a cancer cells' response to DNA damage.The candidate, when orally dosed, reduces cancer growth rates compared to treatment with the same dose of chemotherapeutic without the Chk1 inhibitor, Sareum said."The selection of a preclinical development candidate is a major milestone for the collaboration that will significantly enhance the licensing package," chief executive Tim Mitchell said."Our research indicates that the selectivity and oral dosing properties of this candidate give it a competitive advantage."Shares in drug efficiency modeller Physiomics jumped in sympathy with Sareum. Sareum and Physiomics last year signed an agreement for Physiomics to support Sareum's cancer drug joint research program with the ICR and cancer discovery group Cancer Research Technology.At 12.20pm shares in Sareum were up by 10% at 1.61p, while Physiomics's moved up 13% to 0.39p.